Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy

Diabetes/Metabolism Research and Reviews - Tập 28 Số S1 - Trang 8-14 - 2012
Solomon Tesfaye1, Dinesh Selvarajah1
1Sheffield Teaching Hospitals, Sheffield, UK

Tóm tắt

SUMMARYDiabetic peripheral neuropathy (DPN) affects up to 50% of patients with diabetes and is a major cause of morbidity and increased mortality. Its clinical manifestations include painful neuropathic symptoms and insensitivity, which increases the risk for burns, injuries and foot ulceration.Several recent studies have implicated poor glycaemic control, duration of diabetes, hyperlipidaemia (particularly hypertryglyceridaemia), elevated albumin excretion rates and obesity as risk factors for the development of DPN.Although there is now strong evidence for the importance of nerve microvascular disease in the pathogenesis of DPN, the risk factors for painful DPN are not known. However, emerging evidence regarding the central correlates of painful DPN is now afforded by brain imaging.The diagnosis of DPN begins with a careful history of sensory and motor symptoms. The quality and severity of neuropathic pain if present should be assessed using a suitable scale. Clinical examination should include inspection of the feet and evaluation of reflexes and sensory responses to vibration, light touch, pinprick and the 10‐g monofilament.Glycaemic control and addressing cardiovascular risk is now considered important in the overall management of the neuropathic patient. Pharmacological treatment of painful DPN includes tricyclic compounds, serotonin–norepinephrine reuptake inhibitors (e.g. duloxetine), anticonvulsants (e.g. pregabalin), opiates, membrane stabilizers, the antioxidant alpha lipoic acid and others. Over the past 7 years, new agents with perhaps less side effect profiles have immerged. Management of patients with painful neuropathy must be tailored to individual requirements and will depend on the presence of other co‐morbidities. There is limited literature with regard to combination treatment. Copyright © 2012 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1111/j.2040-1124.2010.00083.x

http://www.idf.org/diabetesatlas/diabetes‐and‐impaired‐glucose‐tolerance

10.2337/diacare.26.6.1790

10.2337/dc10-1303

10.2337/dc05-2228

10.1002/dmrr.360

10.1016/j.jpainsymman.2005.04.009

10.1056/NEJMcp032966

10.1007/s001250050586

10.1056/NEJMoa032782

10.2337/dc07-1796

10.2337/db09-0047

10.2337/db08-1771

10.1007/s001250051062

10.1016/S0895-4356(99)00170-5

10.1007/s001250100001

10.1007/BF00402283

10.1136/bmj.293.6554.1053

10.1007/BF00400804

10.1002/dmrr.1225

10.1046/j.1464-5491.2002.00801.x

10.1007/s00125-003-1127-3

10.2337/dc06-2154

10.2337/diacare.29.04.06.dc05-2180

10.2337/dc10-1550

10.2337/dc09-2314

10.2337/diabetes.55.04.06.db05-1323

10.1007/s11892-011-0205-z

10.1016/S0140-6736(96)02467-1

10.1016/S0140-6736(00)05268-5

10.2337/dc06-0650

10.1152/jn.1999.82.4.1865

10.1016/0959-4388(94)90056-6

10.1007/s00125-008-1139-0

10.1016/j.brainres.2009.02.063

10.1038/nrneurol.2010.90

10.1038/nrneurol.2011.4

10.1073/pnas.96.14.7705

10.1016/S0304-3959(99)00145-1

10.1016/j.neuron.2007.07.012

Wilkinson ID, 2007, Functional MRI and response to pain in diabetic neuropathy, Diabet Med, 24, P187

10.1016/j.neuroimage.2006.03.024

Selvarajah D, 2011, Diabetologia, 1, S81

10.1111/j.1464-5491.2004.01109.x

Thông tin
Thông tin xuất bản

Diabetes/Metabolism Research and Reviews

Tập 28 Số S1

8-14

Thông tin tác giả